Abstract:Today, persistent and uncontrolled inflammation is appreciated to play a pivotal role in many diseases, such as cardiovascular diseases, neurodegenerative diseases, metabolic syndrome and many other diseases of public health concern (e.g. Coronavirus Disease 2019 (COVID-19) and periodontal disease). The ideal response to initial challenge in humans is a self-limited inflammatory response leading to complete resolution. The resolution phase is now widely recognized as a biosynthetically active process, governed by a superfamily of endogenous chemical mediators that stimulate resolution of inflammatory responses, namely specialized proresolving mediators (SPMs). Because resolution is the natural ideal response, the SPMs have gained attention. SPMs are mediators that include ω-6 arachidonic acid-derived lipoxins, ω-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)-derived resolvins, protectins and maresins, cysteinyl-SPMs, as well as n-3 docosapentaenoic acid (DPA)-derived SPMs. These novel immunoresolvents, their biosynthetic pathways and receptors have proven to promote resolution of inflammation, clearance of microbes, reduce pain and promote tissue regeneration via specific cellular and molecular mechanisms. As of 17 August, 2020, PubMed.gov reported >1170 publications for resolvins, confirming their potent protective actions from many laboratories worldwide. Since this field is rapidly expanding, we provide a short update of advances within 2-3 years from human and preclinical animal studies, together with the structural-functional elucidation of SPMs and identification of novel SPM receptors. These new discoveries indicate that SPMs, their pathways and receptors could provide a basis for new approaches for treating inflammation-associated diseases and for stimulating tissue regeneration via resolution pharmacology and precision nutrition.

Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators

Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus

Pro-resolving lipid mediators are leads for resolution physiology

Resolvin E1 and protectin D1 activate inflammation-resolution programmes

Advance in Pro-Resolution Lipid Mediators and Mechanisms of Inflammation Resolution

Resolvins and protectins in the termination program of acute inflammation

Anti-inflammatory lipid mediators and insights into the resolution of inflammation

Specialized pro-resolving mediators - Key players in resolution

Proresolving Lipid Mediators in the Respiratory System

Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution

Specialized pro-resolving mediator network: an update on production and actions

Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease

Old and new generation lipid mediators in acute inflammation and resolution

Resolution medicine in cancer, infection, pain and inflammation: are we on track to address the next Pandemic?

Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: a new therapeutic approach for immune disorders

Self-Limited Versus Delayed Resolution of Acute Inflammation: Temporal Regulation of Pro-Resolving Mediators and MicroRNA

New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases

Low-dose pro-resolving mediators temporally reset the resolution response to microbial inflammation

[Mechanism of Resolvins in Reducing the Inflammation Reaction in Inflammatory Diseases].

Resolvins, Specialized Proresolving Lipid Mediators, and Their Potential Roles in Metabolic Diseases

The resolution of inflammation through omega-3 fatty acids in atherosclerosis, intimal hyperplasia, and vascular calcification